Literature DB >> 32536693

Antiviral Therapy during the Coronavirus Disease (COVID-19) Pandemic: Is It Appropriate to Treat Patients in the Absence of Significant Evidence?

.   

Abstract

Entities:  

Year:  2020        PMID： 32536693      PMCID： PMC7269638     

Source DB:  PubMed          Journal:  Can J Hosp Pharm        ISSN： 0008-4123


× No keyword cloud information.
  17 in total

1.  Reconsidering the ethical permissibility of the use of unregistered interventions against Ebola virus disease.

Authors:  Joshua T Landry; Thomas Foreman; Michael Kekewich
Journal:  Camb Q Healthc Ethics       Date:  2015-07       Impact factor: 1.284

2.  Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children.

Authors:  Catherine Liu; Arnold Bayer; Sara E Cosgrove; Robert S Daum; Scott K Fridkin; Rachel J Gorwitz; Sheldon L Kaplan; Adolf W Karchmer; Donald P Levine; Barbara E Murray; Michael J Rybak; David A Talan; Henry F Chambers
Journal:  Clin Infect Dis       Date:  2011-01-04       Impact factor: 9.079

3.  Examining the ethics of clinical use of unproven interventions outside of clinical trials during the Ebola epidemic.

Authors:  Seema K Shah; David Wendler; Marion Danis
Journal:  Am J Bioeth       Date:  2015       Impact factor: 11.229

Review 4.  Infective Endocarditis in Adults: Diagnosis, Antimicrobial Therapy, and Management of Complications: A Scientific Statement for Healthcare Professionals From the American Heart Association.

Authors:  Larry M Baddour; Walter R Wilson; Arnold S Bayer; Vance G Fowler; Imad M Tleyjeh; Michael J Rybak; Bruno Barsic; Peter B Lockhart; Michael H Gewitz; Matthew E Levison; Ann F Bolger; James M Steckelberg; Robert S Baltimore; Anne M Fink; Patrick O'Gara; Kathryn A Taubert
Journal:  Circulation       Date:  2015-09-15       Impact factor: 29.690

5.  Social value, clinical equipoise, and research in a public health emergency.

Authors:  Alex John London
Journal:  Bioethics       Date:  2018-07-27       Impact factor: 1.898

Review 6.  Possible Consequences of a Shortage of Hydroxychloroquine for Patients with Systemic Lupus Erythematosus amid the COVID-19 Pandemic.

Authors:  Christine A Peschken
Journal:  J Rheumatol       Date:  2020-04-08       Impact factor: 4.666

Review 7.  SARS: systematic review of treatment effects.

Authors:  Lauren J Stockman; Richard Bellamy; Paul Garner
Journal:  PLoS Med       Date:  2006-09       Impact factor: 11.069

8.  Paradoxical Effect of Chloroquine Treatment in Enhancing Chikungunya Virus Infection.

Authors:  Pierre Roques; Simon-Djamel Thiberville; Laurence Dupuis-Maguiraga; Fok-Moon Lum; Karine Labadie; Frédéric Martinon; Gabriel Gras; Pierre Lebon; Lisa F P Ng; Xavier de Lamballerie; Roger Le Grand
Journal:  Viruses       Date:  2018-05-17       Impact factor: 5.048

9.  In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).

Authors:  Xueting Yao; Fei Ye; Miao Zhang; Cheng Cui; Baoying Huang; Peihua Niu; Xu Liu; Li Zhao; Erdan Dong; Chunli Song; Siyan Zhan; Roujian Lu; Haiyan Li; Wenjie Tan; Dongyang Liu
Journal:  Clin Infect Dis       Date:  2020-07-28       Impact factor: 9.079

10.  A Rush to Judgment? Rapid Reporting and Dissemination of Results and Its Consequences Regarding the Use of Hydroxychloroquine for COVID-19.

Authors:  Alfred H J Kim; Jeffrey A Sparks; Jean W Liew; Michael S Putman; Francis Berenbaum; Alí Duarte-García; Elizabeth R Graef; Peter Korsten; Sebastian E Sattui; Emily Sirotich; Manuel F Ugarte-Gil; Kate Webb; Rebecca Grainger
Journal:  Ann Intern Med       Date:  2020-03-30       Impact factor: 25.391
View more
  1 in total

1.  Response to: Regarding the Article: A Multimodal Strategy to Reduce the Risk of Hospitalization/death in Ambulatory Patients with COVID-19.

Authors:  César Raúl Gonzalez Bonilla
Journal:  Arch Med Res       Date:  2022-05-10       Impact factor: 8.323
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.